On October 16, 2026, the FDA converted Keytruda's approval for TMB-high solid tumors from accelerated to full — and raised the cutoff from 10 to 13 mutations per megabase. Here is what tumor mutational burden means, why the line moved, and what it means if your score was 10, 11, or 12.